MONT-SAINT-GUIBERT, Belgium, Jan. 26, 2015 /PRNewswire/ -- Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announces agenda and webcast details for its 2015 Investor & Analyst Day being held Friday, January 30 in New York, NY from 8:00 a.m. - 12:00 p.m. ET.
The agenda will include:
Introduction & Welcome Dr. Christian Homsy, Chief
Executive Officer, C3BS
Regenerative Medicine for Cardiac Dr. Andre Terzic, Director, Center
Indications for Regenerative Medicine, Mayo
Clinic
Dr. Atta Behfar, Assistant
Professor of Medicine and Senior
Associate Consultant, Division of
Cardiovascular Diseases, Mayo
Clinic
Dr. Jozef Bartunek, Associate
Director, Cardiovascular Centre,
Aalst Belgium
Dr. Thomas Povsic, Associate
Professor of Medicine and
Interventional Heart Specialist,
Duke Medicine
Dr. Amit Patel, Director of
Cardiovascular Regenerative
Medicine, University of Utah
School of Medicine Division of
Cardiothoracic Surgery
Dr. Warren Sherman, Chief Medical
Officer, C3BS
Immunotherapy & Dr. Ivan Borrello, Associate
Professor of Oncology, Sidney
Kimmel Comprehensive Cancer
Center, Johns Hopkins Medicine
CAR T-Cell Technology
Dr. Charles Sentman, Professor of
Microbiology and Immunology and
Director, Center for Synthetic
Immunity, Geisel School of
Medicine, Dartmouth College
Dr. Susanne Baumeister, Attending
Physician, Hematology & Oncology,
Dana-Farber Cancer Institute
Dr. David Ghilham, Clinical and
Experimental Immunotherapy Group,
Institute of Cancer Sciences,
University of Manchester, United
Kingdom
Dr. Vincent Brichard, VP Immuno-
Oncology, C3BS
C3BS' Financial Strategy Patrick Jeanmart, Chief Financial
Officer, C3BS
Closing Remarks Michel Lussier, Chairman of the
Board, C3BS
Following the event, an archived audio webcast with slide presentation will be available by visiting the Events section of Cardio3's website at http://www.c3bs.com/en/events. The webcast will be available on the Cardio3 website for one year.
Attendance at The Cardio3 BioSciences Analyst Day is by invitation only.
To request an invitation for the event, please contact Taylor Donovan of The Ruth Group at tdonovan@theruthgroup.com or +1 646-536-7017.
For more information, please contact:
Cardio3 BioSciences www.c3bs.com
Christian Homsy, CEO Tel: +32 10 39 41 00
Julie Grade, Corporate Communications Manager jgrade@c3bs.com
For Europe: Consilium Strategic Communications Tel : +44 20 3709 5700
Amber Bielecka, Chris Welsh, Laura Thornton cardio3@consilium-comms.com
For the U.S: The Ruth Group Tel: +1 646 536 7012 / 7014
Lee Roth (Investors), Kirsten Thomas (Media) lroth@theruthgroup.com
kthomas@theruthgroup.com
To subscribe to Cardio3 BioSciences' newsletter, visit www.c3bs.com.
Follow us on Twitter @Cardio3Bio.
About Cardio3 BioSciences
Cardio3 BioSciences is a leading biotechnology company focused on the discovery and development of cell therapies for the treatment of unmet medical needs in cardiology and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA and in Europe with the Mayo Clinic (MN, USA) and Dartmouth College (NH, USA). The Company's lead product candidate in cardiology is C-Cure®, an autologous stem cell therapeutic using guided stem cells for the condition of congestive heart failure. The Company's lead product candidate in oncology is CM-CS1, an autologous CAR T-Cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumor types, including hematologic cancers and solid tumors. Cardio3 BioSciences is also developing a portfolio of medical devices for enhancing the delivery of bio therapeutic agents into the myocardium (C-Cath(ez)®) and for cardiac surgery involving mitral valve defects.
Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.
To learn more about Cardio3 BioSciences, please visit www.c3bs.com
C3BS-CQR-1, C-Cure, CM-CS1, C-Cath(ez), OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences, C-Cath(ez), CHART-1, CHART-2 and OnCyte logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cardio3-biosciences-announces-agenda-and-webcast-for-2015-nyc-investor-day-300025590.html
SOURCE Cardio3 BioSciences
